TNFRSF17 and plasma cell myeloma: Close monitoring to ensure early recognition of infection, as well as the institution of antimicrobial prophylaxis and immunoglobulin replacement therapy, should be a priority for patients with multiple myeloma receiving BCMA-targeted T-cell-redirecting therapies36.